- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07659925
Periodization-Based Strength Exercise Training in İndividuals With Type 2 Diabetes (T2DM_NLP)
A Comparison of the Effects of Different Periodization-Based Strength Training Programs in Individuals With Type 2 Diabetes Mellitus
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Type 2 diabetes mellitus is associated with reduced exercise capacity, decreased muscle strength, impaired quality of life, and metabolic dysfunction. Exercise training is recommended as an important component of diabetes management; however, the comparative effectiveness of different strength training periodization approaches remains unclear.
This randomized controlled trial aims to compare the effects of non-linear periodization and linear periodization strength training programs in individuals with type 2 diabetes mellitus. Participants will be randomized into three groups: a non-linear periodization training group, a linear periodization training group, and a control group receiving usual care.
The intervention will be conducted for 8 weeks, three times per week. Outcomes including exercise capacity, muscle strength, body composition, quality of life, and metabolic parameters will be evaluated before and after the intervention period.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ayşegül Erkoç, PT
- Numéro de téléphone: +90 553-301-36-73
- E-mail: erkcaysegl@gmail.com
Lieux d'étude
-
-
Ankara
-
Ankara, Ankara, Turquie (Türkiye), 06790
- Recrutement
- Baskent University Hospital
-
Contact:
- Ayşegül Erkoç, PT
- Numéro de téléphone: +90 553-301-36-73
- E-mail: erkcaysegl@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults aged between 18 to 65 years
- Diagnosis of Type 2 Diabetes Mellitus (T2DM)
- Not having participated in any structured exercise program within the last 6 months
- Willingness to participate in the study and provide written informed consent
Exclusion Criteria:
- Presence of nephropathy, retinopathy, or peripheral neuropathy
- Presence of neurological, cognitive, or orthopedic disorders that may affect outcome measurements
- Severe respiratory disease (Forced Expiratory Volume in the first second [FEV1] <35% or Forced Vital Capacity [FVC] <50%)
- Presence of ischemic heart disease or peripheral arterial disease
- History of any cardiovascular event within the last 6 months
- Current malignancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Non-linear Periodization Group
Participants will receive non-linear periodization-based strength training three times per week for 8 weeks.
|
Participants will perform supervised non-linear periodization-based strength training three times per week for 8 weeks.
|
|
Expérimental: Linear Periodization Group
Participants will receive linear periodization-based strength training three times per week for 8 weeks.
|
Participants will perform supervised linear periodization-based strength training three times per week for 8 weeks.
|
|
Comparateur actif: Control Group
Participants will receive usual care and no structured exercise intervention during the study period.
|
Participants will receive usual care and no structured exercise intervention during the study period.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Exercise Capacity
Délai: Baseline and after 8 week
|
Exercise capacity will be assessed using the 6-Minute Walk Test (6MWT)
|
Baseline and after 8 week
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Peripheral Muscle Strength
Délai: Baseline and after 8 weeks
|
Peripheral muscle strength will be assessed using handheld dynamometry for upper and lower extremity muscle groups and reported in Newton (N).
|
Baseline and after 8 weeks
|
|
Change in Hand Grip Strength
Délai: Baseline and after 8 weeks
|
Hand grip strength will be assessed using a hand dynamometer and reported in kilograms (kg).
|
Baseline and after 8 weeks
|
|
Change in Diabetes Quality of Life Questionnaire Score
Délai: Baseline and after 8 weeks
|
Change in the Turkish version of the Diabetes Quality of Life Questionnaire (DQOL) total score and subscale scores from baseline to 8 weeks will be evaluated.
The DQOL consists of 45 items assessing treatment satisfaction, psychological impact, concerns about future effects of diabetes, and social/vocational concerns.
Each item is scored on a 1-5 scale, and higher scores indicate better diabetes-related quality of life.
|
Baseline and after 8 weeks
|
|
Change in Body Fat Percentage
Délai: Baseline and after 8 weeks
|
Body fat percentage (%) will be assessed using bioelectrical impedance analysis (BIA).
|
Baseline and after 8 weeks
|
|
Change in Skeletal Muscle Mass
Délai: Baseline and after 8 weeks
|
Skeletal muscle mass (kg) will be assessed using bioelectrical impedance analysis (BIA).
|
Baseline and after 8 weeks
|
|
Change in Resting Metabolic Rate
Délai: Baseline and after 8 weeks
|
Resting metabolic rate (kcal/day) will be assessed using indirect calorimetry (COSMED Fitmate Pro, Rome, Italy).
|
Baseline and after 8 weeks
|
|
Change in Hemoglobin A1c (HbA1c)
Délai: Baseline and after 8 weeks
|
Glycemic control will be assessed by measuring glycated hemoglobin (HbA1c) levels (%).
|
Baseline and after 8 weeks
|
|
Change in Fasting Blood Glucose
Délai: Baseline and after 8 weeks
|
Glycemic control will be assessed by measuring fasting blood glucose levels (mg/dL).
|
Baseline and after 8 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Neslihan Duruturk, PhD, Baskent University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- T2DM-NLP-2026
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .